SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-008965
Filing Date
2023-02-07
Accepted
2023-02-07 16:10:44
Documents
12
Period of Report
2023-02-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea172745-8k_unicycive.htm   iXBRL 8-K 26895
  Complete submission text file 0001213900-23-008965.txt   202500

Data Files

Seq Description Document Type Size
2 XBRL LABEL FILE uncy-20230201_lab.xml EX-101.LAB 34240
3 XBRL PRESENTATION FILE uncy-20230201_pre.xml EX-101.PRE 22361
4 XBRL SCHEMA FILE uncy-20230201.xsd EX-101.SCH 3230
6 EXTRACTED XBRL INSTANCE DOCUMENT ea172745-8k_unicycive_htm.xml XML 3710
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 23595173
SIC: 2834 Pharmaceutical Preparations